Pathkey.AI Ltd
Opyl Limited is an Australia-based artificial intelligence (AI) company.
The business
Opyl Limited is an Australia-based artificial intelligence (AI) company. The Company leverages data and technology to transform the landscape of clinical trials and medical research. It is a digital health company, specialized in leveraging artificial intelligence technologies to elevate clinical trial design and forecast outcomes, empowering clinical researchers, biopharmaceutical corporations, and medical investors to enhance trial design, drug development, and market delivery. Its Social Media Insights solution captures and analyses online public conversations from people living with a medical condition, healthcare professionals, carers, and researchers. Its TrialKey platform provides users access to tailored, actionable steps to address critical trial challenges, improving the likelihood of success. The Company is specialized in applying AI and predictive analytics to social media to accelerate therapy adoption and market development in the healthcare industry.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Pathkey.AI Moves to Add Semiconductor Design Platform through Chipforge Acquisition
Pathkey.AI to acquire Chipforge, expanding AI into semiconductor design; irrevocable option to buy 100% within 2 months, via 560 million Pathkey shares.

Pathkey.AI Lands Largest Contract Yet for TrialKey Platform with Imunexus Therapeutics
Pathkey.AI lands its biggest deal yet with Imunexus for TrialKey, up to $100k (incl. $25k upfront); remainder tied to capital raises—1-year pact.

Pathkey.AI Validates TrialKey With Strong Alignment To Clinical Outcomes
Pathkey.AI (ASX: PKY) has unveiled its first validation study of the TrialKey platform, an AI tool to predict clinical trial success. The company reported that TrialKey correctly aligned with 73% of trial outcomes across 11 clinical programs that reported results between March and July 2025. Management said the findings mark a critical step in proving […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.